Legal & General Group Plc Takes $21.86 Million Position in Medpace Holdings, Inc. $MEDP

Key Points

• Legal & General Group Plc acquired 41,268 Medpace shares worth approximately $21.86 million, representing about 0.15% of the company. Institutional investors collectively own 77.98% of Medpace.
• Medpace reported quarterly EPS of $4.25, exceeding estimates of $3.98, while revenue rose 17.2% year over year to $707.33 million. The company guided to fiscal 2026 EPS of $17.25–$17.95.
• Analysts raised several price targets, but the consensus rating remains “Hold” with an average target of $584.18. Medpace shares opened at $600.65, while company insiders sold roughly $81.75 million of stock during the last quarter.

Legal & General Group Plc bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 41,268 shares of the company's stock, valued at approximately $21,855,000. Legal & General Group Plc owned approximately 0.15% of Medpace at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of MEDP. The Manufacturers Life Insurance Company purchased a new position in shares of Medpace during the 2nd quarter valued at approximately $10,615,000. Jones Financial Companies Lllp acquired a new position in Medpace during the second quarter worth about $30,000. Womack Financial LLC purchased a new stake in shares of Medpace in the second quarter valued at approximately $1,152,000. Ranger Investment Management L.P. purchased a new stake in Medpace in the 2nd quarter valued at $14,230,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in Medpace during the second quarter worth about $2,134,000. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Trading Down 1.8%

Shares of MEDP stock opened at $600.65 on Friday. The company has a market capitalization of $16.77 billion, a P/E ratio of 35.21, a price-to-earnings-growth ratio of 2.68 and a beta of 1.15. The business's 50 day moving average is $565.33 and its two-hundred day moving average is $494.55. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts' consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. Medpace's quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MEDP has been the topic of a number of research analyst reports. Weiss Ratings upgraded Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, August 12th. Royal Bank Of Canada increased their target price on shares of Medpace from $484.00 to $692.00 and gave the stock an "outperform" rating in a report on Friday, July 24th. Mizuho lifted their price objective on Medpace from $586.00 to $665.00 and gave the company an "outperform" rating in a research note on Friday, July 24th. Truist Financial lifted their price objective on shares of Medpace from $462.00 to $609.00 and gave the stock a "hold" rating in a research report on Friday, July 24th. Finally, Robert W. Baird upped their price target on Medpace from $547.00 to $624.00 and gave the company a "neutral" rating in a report on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $584.18.

Insider Buying and Selling

In other news, CEO August J. Troendle sold 4,000 shares of the business's stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $620.03, for a total transaction of $2,480,120.00. Following the sale, the chief executive officer owned 540,544 shares of the company's stock, valued at $335,153,496.32. The trade was a 0.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Fred B. Davenport, Jr. sold 7,283 shares of the company's stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total value of $4,414,590.45. Following the completion of the sale, the director directly owned 3,798 shares in the company, valued at $2,302,157.70. This trade represents a 65.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 133,821 shares of company stock valued at $81,748,135 in the last quarter. Corporate insiders own 20.50% of the company's stock.

About Medpace

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source